The human amniotic fluid stem cell secretome effectively counteracts doxorubicin-induced cardiotoxicity

Scientific Reports

27 Luglio Lug 2016 4 months ago
  • Gambini E, Pompilio G

The anthracycline doxorubicin (Dox) is widely used in oncology, but it may cause a cardiomyopathy with bleak prognosis that cannot be effectively prevented. The secretome of human amniotic fluid-derived stem cells (hAFS) has previously been demonstrated to significantly reduce ischemic cardiac damage. Here it is shown that, following hypoxic preconditioning, hAFS conditioned medium (hAFS-CM) antagonizes senescence and apoptosis of cardiomyocytes and cardiac progenitor cells, two major features of Dox cardiotoxicity.

Reference
Lazzarini E, Balbi C, Altieri P, Pfeffer U, Gambini E, Canepa M, Varesio L, Bosco MC, Coviello D, Pompilio G, Brunelli C, Cancedda R, Ameri P, Bollini S. The human amniotic fluid stem cell secretome effectively counteracts doxorubicin-induced cardiotoxicity. Sci Rep 2016;6:29994

Go to PubMed